British Association of Dermatologists  
Response to NICE Appraisal Consultation Document  
On the Multiple Technology Appraisal (MTA)  
Certolizumab pegol and secukinumab for treating active psoriatic arthritis following inadequate response to disease modifying anti-rheumatic drugs [ID579].  

British Association of Dermatologists  
Therapy & Guidelines and BADBIR sub-committees

On behalf of the British Association of Dermatologists, thank you for the opportunity to comment on the Appraisal Consultation Document. The British Association of Dermatologists have no comments.

Dr Pamela McHenry  
Chair, Therapy & Guidelines sub-committee